PD-1抗体nivolumab治疗肺癌脑转移:疗效不佳
  • 晚期非小细胞肺癌(NSCLC)中枢神经系统转移(CNS)的发生率30%,总体生存期(OS)差;
  • CheckMate 017和057研究中,与多西紫杉醇相比,免疫检查点抑制剂抗体nivolumab治疗NSCLC患者延长生存期;
  • 回顾性分析接受nivolumab治疗的48例NSCLC患者;
  • A组29例(60%)患者无CNS转移,B组19例 (40%)患者存在脑转移(BM),B组中,15例(79%)患者接受BM的放疗(RT),A组的PFS较B组长,nivolumab治疗CNS转移灶,无缓解者;
  • 需要纳入更多病例进行前瞻性研究。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer

Nivolumab对非小细胞肺癌中枢神经系统转移的治疗作用

2017-06-03

Abstract & Authors:展开

Abstract:收起
Background: Central nervous system (CNS) metastases (mets) occur in 30% of patients with advanced non-small cell lung cancer (NSCLC) and are associated with poor overall survival (OS). Although nivolumab, a programmed death-1 immune checkpoint inhibitor antibody, has demonstrated a longer survival benefit compared with docetaxel in previously treated NSCLC patients (CheckMate 017 and 057; N Engl J Med, 2015), patients with symptomatic or untreated CNS mets were excluded in these trials. In CheckMate 012 Arm M, 2 of 12 patients (16.7%) with untreated CNS mets showed intracranial responses, but the effect of nivolumab treatment for CNS mets was not fully investigated.
Methods: To investigate the effect and safety of nivolumab for CNS mets in NSCLC patients, we retrospectively analyzed 48 patients with NSCLC who were treated with nivolumab from February 2016 to December 2016 at Okayama University Hospital.
Results: Twenty-nine patients (60%) had no CNS lesions (group A) and 19 patients (40%) had brain mets (BM) (group B). In group B, 15 patients (79%) received radiotherapy (RT) for BM, including 5 patients who received RT just before nivolumab treatment. The responses of extra-CNS lesions to nivolumab are shown in the table. The PFS was longer in group A than in group B (p=0.14). In group B, the PFS of patients who received prior RT tended to be longer than in those without RT (p=0.42); OS was not reached in either group. In group B, the effects of nivolumab treatment for CNS mets were evaluated in 12 patients: SD occurred in 3 patients (25%), PD in 4 patients (33%), and NE in 5 patients (42%). All 4 patients with PD in the CNS lesion also showed PD in the extra-CNS lesion. In group A, no patients showed progression only in the CNS lesion.
Conclusions: In this retrospective study, there were no patients treated only with nivolumab who showed a response to CNS mets. RT prior to nivolumab might be more effective, so future investigations should involve additional cases and prospective studies.

All Authors:
Hiromi Watanabe

评论